Upgrade to SI Premium - Free Trial

Cytokinetics (CYTK) PT Lowered to $104 at UBS

October 14, 2026 6:51 AM
UBS analyst Ashwani Verma lowered the price target on Cytokinetics (NASDAQ: CYTK) to $104.00 (from $115.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change